A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice

Area of Science:

• Pharmacology
• Neuroscience
• Addiction Research

Background:

• Opioid dependence is a major public health concern.
• Understanding the mechanisms of opioid dependence is crucial for developing effective treatments.
• Kappa-opioid receptors are implicated in various aspects of opioid action and dependence.

Purpose of the Study:

• To investigate the effects of a novel kappa-opioid receptor agonist, TRK-820, on the development of physical dependence on morphine in mice.
• To compare the efficacy of TRK-820 with another kappa-opioid receptor agonist, U-50,488H, in modulating morphine dependence.

Main Methods:

• Morphine dependence was induced in mice through chronic treatment.
• Naloxone challenge was used to precipitate withdrawal symptoms.
• TRK-820 and U-50,488H were co-administered with morphine during the treatment period.
• Withdrawal signs, including body weight loss, jumping, wet dog shakes, and diarrhea, were assessed.

Main Results:

• Morphine-dependent mice exhibited significant body weight loss and withdrawal signs upon naloxone challenge.
• Co-administration of TRK-820 (0.003-0.03 mg/kg) dose-dependently suppressed naloxone-precipitated body weight loss and withdrawal symptoms.
• U-50,488H (1-10 mg/kg) did not show significant effects in suppressing these withdrawal signs.
• TRK-820 demonstrated a notable suppressive effect on the development of physical dependence on morphine.

Conclusions:

• TRK-820 effectively suppresses the development of physical dependence on morphine in a mouse model.
• These findings highlight the potential role of TRK-820-sensitive kappa-opioid receptor subtypes in modulating opioid physical dependence.
• TRK-820 represents a promising therapeutic candidate for managing or preventing opioid dependence.